HKSE:06826 (China)
Â
Shs -H- Unitary 144A/Reg S
HK$
40.15
(+0.63%)
Apr 25
Current and historical daily PE Ratio for Shanghai Haohai Biological Technology Co Ltd (
HKSE:06826
) from 2015 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Shanghai Haohai Biological Technology stock (HKSE:06826) PE ratio as of Apr 25 2024 is 14.99.
More Details
Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) PE Ratio (TTM) Chart
Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Total 1193
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Shanghai Haohai Biological Technology PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | 15.1 | 2024-02-20 | 13.4 |
| 2024-04-25 | 15.1 | 2024-02-19 | 13.2 |
| 2024-04-24 | 15.0 | 2024-02-16 | 13.4 |
| 2024-04-23 | 14.4 | 2024-02-15 | 13.0 |
| 2024-04-22 | 14.3 | 2024-02-14 | 12.9 |
| 2024-04-19 | 14.1 | 2024-02-09 | 13.0 |
| 2024-04-18 | 14.7 | 2024-02-08 | 13.0 |
| 2024-04-17 | 14.4 | 2024-02-07 | 12.7 |
| 2024-04-16 | 14.2 | 2024-02-06 | 12.7 |
| 2024-04-15 | 14.4 | 2024-02-05 | 11.8 |
| 2024-04-12 | 14.6 | 2024-02-02 | 12.2 |
| 2024-04-11 | 14.9 | 2024-02-01 | 12.5 |
| 2024-04-10 | 15.1 | 2024-01-31 | 12.2 |
| 2024-04-09 | 15.1 | 2024-01-30 | 13.1 |
| 2024-04-08 | 14.7 | 2024-01-29 | 13.9 |
| 2024-04-05 | 14.3 | 2024-01-26 | 13.6 |
| 2024-04-03 | 14.8 | 2024-01-25 | 14.2 |
| 2024-04-02 | 14.9 | 2024-01-24 | 14.0 |
| 2024-03-28 | 15.1 | 2024-01-23 | 13.9 |
| 2024-03-27 | 14.9 | 2024-01-22 | 13.4 |
| 2024-03-26 | 14.8 | 2024-01-19 | 14.0 |
| 2024-03-25 | 15.1 | 2024-01-18 | 14.3 |
| 2024-03-22 | 15.5 | 2024-01-17 | 14.3 |
| 2024-03-21 | 15.8 | 2024-01-16 | 14.9 |
| 2024-03-20 | 15.9 | 2024-01-15 | 15.0 |
| 2024-03-19 | 15.6 | 2024-01-12 | 15.1 |
| 2024-03-18 | 15.8 | 2024-01-11 | 14.7 |
| 2024-03-15 | 15.4 | 2024-01-10 | 14.7 |
| 2024-03-14 | 15.5 | 2024-01-09 | 14.5 |
| 2024-03-13 | 16.0 | 2024-01-08 | 14.2 |
| 2024-03-12 | 15.1 | 2024-01-05 | 14.5 |
| 2024-03-11 | 14.8 | 2024-01-04 | 14.5 |
| 2024-03-08 | 14.1 | 2024-01-03 | 14.5 |
| 2024-03-07 | 13.6 | 2024-01-02 | 14.3 |
| 2024-03-06 | 14.2 | 2023-12-29 | 15.2 |
| 2024-03-05 | 13.9 | 2023-12-28 | 14.9 |
| 2024-03-04 | 14.2 | 2023-12-27 | 17.8 |
| 2024-03-01 | 13.9 | 2023-12-22 | 17.0 |
| 2024-02-29 | 13.8 | 2023-12-21 | 17.9 |
| 2024-02-28 | 13.6 | 2023-12-20 | 17.7 |
| 2024-02-27 | 14.1 | 2023-12-19 | 18.1 |
| 2024-02-26 | 13.9 | 2023-12-18 | 18.2 |
| 2024-02-23 | 13.7 | 2023-12-15 | 18.6 |
| 2024-02-22 | 13.9 | 2023-12-14 | 18.6 |
| 2024-02-21 | 13.9 | 2023-12-13 | 18.5 |
Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Shanghai Haohai Biological Technology Co Ltd
ISIN : CNE100001W69
Share Class Description:
HKSE:06826: Shs -H- Unitary 144A/Reg SCompare
Compare
Traded in other countries / regions
688366.China06826.Hong Kong5HB.Germany IPO Date
2015-04-30Description
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers